THRP Stock Overview
Develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ThermoGenesis Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.28 |
| 52 Week High | US$6.16 |
| 52 Week Low | US$1.03 |
| Beta | 2.49 |
| 11 Month Change | 0% |
| 3 Month Change | 1.59% |
| 1 Year Change | n/a |
| 33 Year Change | -98.70% |
| 5 Year Change | n/a |
| Change since IPO | -98.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| THRP | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.0% | 0.4% |
| 1Y | n/a | 1.8% | 3.9% |
Return vs Industry: Insufficient data to determine how THRP performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how THRP performed against the German Market.
Price Volatility
| THRP volatility | |
|---|---|
| THRP Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: THRP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine THRP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 41 | Chris Xu | www.thermogenesis.com |
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications.
ThermoGenesis Holdings, Inc. Fundamentals Summary
| THRP fundamental statistics | |
|---|---|
| Market cap | €3.37m |
| Earnings (TTM) | -€13.22m |
| Revenue (TTM) | €9.09m |
0.4x
P/S Ratio-0.3x
P/E RatioIs THRP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THRP income statement (TTM) | |
|---|---|
| Revenue | US$9.64m |
| Cost of Revenue | US$7.23m |
| Gross Profit | US$2.41m |
| Other Expenses | US$16.42m |
| Earnings | -US$14.02m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.47 |
| Gross Margin | 24.96% |
| Net Profit Margin | -145.49% |
| Debt/Equity Ratio | 272.6% |
How did THRP perform over the long term?
See historical performance and comparison